liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Commentary: Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. The Annals of Thoracic Surgery, Volume 77, Issue 3, March 2004, Pages 942-949: Invited commentary
Department of Cardiothoracic Surgery, University Hospital, Linkoping, SE-581 85, Sweden.
2004 (English)In: Annals of Thoracic Surgery, ISSN 0003-4975, Vol. 77, no 3, 949-950 p.949-950 p.Article in journal, Editorial material (Other academic) Published
Abstract [en]

[No abstract available]

Place, publisher, year, edition, pages
2004. Vol. 77, no 3, 949-950 p.949-950 p.
Keyword [en]
25
National Category
Natural Sciences
Identifiers
URN: urn:nbn:se:liu:diva-45815DOI: 10.1016/j.athoracsur.2003.10.023OAI: oai:DiVA.org:liu-45815DiVA: diva2:266711
Available from: 2009-10-11 Created: 2009-10-11 Last updated: 2014-07-01Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text
In the same journal
Annals of Thoracic Surgery
Natural Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 15 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf